Using functional magnetic resonance imaging (fMRI), researchers have identified abnormalities in the brains of children with attention deficit/hyperactivity disorder (ADHD) that may serve as a biomarker for the disorder, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Archives for November 2011
GVK Biosciences Announces Multi-year Drug Discovery Collaboration with the Moulder Center for Drug Discovery Research, Temple University
November 28, 2011 Leave a Comment
GVK Biosciences, Asia’s leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.
As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.
AMP Announces Completion of Strategic Plan For Era of Personalized Medicine
November 23, 2011 Leave a Comment
The Association for Molecular Pathology (AMP) recently announced the AMP Council’s unanimous approval of a strategic plan intended to guide the organization over the next four years.
The plan’s completion follows a comprehensive Council review of AMP’s mission and strategic direction. The process was also informed by multiple surveys of membership and elected leadership, as well as numerous field interviews.
AQUA Technology Expands to Additional Digital Pathology Platform with Launch of Vectra 2 from Caliper Life Sciences
November 21, 2011 Leave a Comment
Caliper Life Sciences, a Perkin-Elmer Company, launched their new Vectra 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting this week. Caliper and HistoRx collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry. The new product enables users to leverage the combined imaging and analysis power of Caliper’s Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA technology, HistoRx’s proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.
